Survival Outcomes in Metastatic Prostate Cancer in the Brazilian Population - Analysis of Individual Characteristics and Treatment Modalities in Different National Health Institutions.

Study Overview
=================
Brief Summary
-----------------
Survival outcomes in metastatic prostate cancer in the population Brazilian - analysis of individual characteristics and modalities of treatment in different national health institutions

Official Title
-----------------
Survival Outcomes in Metastatic Prostate Cancer in the Brazilian Population - Analysis of Individual Characteristics and Treatment Modalities in Different National Health Institutions.

Conditions
-----------------
Prostatic Neoplasms, Castration-Resistant

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Diagnosis of castration-resistant metastatic prostate cancer diagnosed in the period between January 2014 and December 2017. Exclusion Criteria: Diagnosis of localized or locally advanced or metastatic disease sensitive to castration; Patients with medical records filled with incomplete data that make it impossible to evaluate the treatment received.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Public institution<br>Castration-resistant metastatic prostate cancer diagnosed between January 2014 and December 2017 | |
| Private institution<br>Castration-resistant metastatic prostate cancer diagnosed between January 2014 and December 2017 | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Describe cause-specific survival in patients with castration-resistant prostate cancer in different institutions in Brazil. |  | December of 2017 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To describe the sociodemographic characteristics of patients with castration-resistant metastatic prostate cancer in Brazil; |  | December of 2017 | 
| To describe comorbidities of patients with castration-resistant metastatic prostate cancer in Brazil; |  | December of 2017 | 
| To describe the clinicopathological characteristics of patients with metastatic castration-resistant prostate cancer in Brazil; |  | December of 2017 | 
| To compare overall survival among patients with castration-resistant metastatic prostate cancer treated in the SUS and in the private network; |  | December of 2017 | 
| To compare the treatments performed by patients with castration-resistant metastatic prostate cancer in the SUS and in the private network; |  | December of 2017 | 
| To describe the rates of skeletal-related complications |  | December of 2017 | 
| To describe the rate of admissions |  | December of 2017 | 
| To describe the number of lines of treatment that patients have undergone |  | December of 2017 | 
| To describe the presence or absence of treatments bone-directed |  | December of 2017 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Prostatic Neoplasms